Friday May 11, 2018

JOINT PLENARY: PRECISION MEDICINE: PATIENT, POPULATION, OR BOTH?

Can Macrodata Predict Response to Therapy?
Larry Allen, MD

Genes to Genomes: Evolution of Molecular Testing for Inherited Cardiomyopathy 
Birgit Funke, PhD 

The Journey of the Biomarker From Bench to Bedside 
Douglas Lee, MD 

PLENARY Q&A

FLASH SCIENCE TRAINEE PRESENTATIONS

CHFS CLINICAL WORKSHOPS I 

CCS Comprehensive HF Guidelines
Michael McDonald, MD; Eileen O'Meara, MD 

Ms. Understood: Gender-based Differences and HF Therapies: Drugs, Devices and Surgery 
Vivek Rao, MD; Shelley Zieroth, MD 

What Patient Advocacy Means in 2018 
Jillianne Code, PhD; Sean Virani, MD

TED ROGERS CENTRE SCIENTIFIC SESSION: HOW TO ENGINEER A HEART 

Biomaterials that Improve Heart Function 
Ren-Ke Li, MD 

The Genomic Blueprint of the Heart 
Benoit Bruneau, MD  

Importance of Vasculature to Heart Regeneration 
Sara Vasconcelos, PhD

TED ROGERS CENTRE SCIENTIFIC SESSION Q&A 

LUNCH SYMPOSIUM

Time to Treatment in HF: The Time Is Now
Jonathan Howlett, MD (Chair); Martin Cowie, MD; Nadia Giannetti, MD; Peter Liu, MD

JOINT PLENARY: EVOLVING CONCEPTS IN HEART FAILURE 

Amlodipine Therapy for Iron-overload Cardiomyopathy: The Enduring Value of Translational Research 
Gavin Oudit, MD 

Heart Failure With and Without Atrial Fibrillation: Are They Different Diseases? 
Martin Cowie, MD

Update on Ischemic Conditioning: Bench to Bedside Opportunities for Clinical Translation 
Nicolas Noiseux, MD 

PLENARY Q&A 

FLASH SCIENCE TRAINEE PRESENTATIONS

CHFS CLINICAL WORKSHOPS II 

Bridging the Gap Between Clinical Medicine and Basic Science: Opening Pandora's Box
Phyllis Billia, MD; Anthony Gramolini, PhD 

Nursing: Managing Goals of Care 
Leah Steinberg, MD; Pat Strachan, RN, PhD 

Cardiorenal Disease 
Nadia Giannetti, MD 

TED ROGERS CENTRE SESSION: CARDIAC SIGNALLING & METABOLISM 

Can Modulating Cardiac Metabolism Prevent HF 
Mansoor Husain, MD 

HDL and Cell Signaling in the Heart: Roles in Cardioprotection 
Bernardo Trigatti, PhD 

Apelin Analogues as Novel Therapies for Cardiovascular Disease 
Gavin Oudit, MD 

Saturday May 12, 2018

BREAKFAST SYMPOSIUM

Questions About Diabetes and HF You Were Too Afraid to Ask 
Shelley Zieroth, MD (Chair); Vineeta Ahooja, MD; Kim Connelly, MBBS, PhD; Elizabeth Swiggum, MD; Subodh Verma, MD, PhD

JOINT PLENARY: SWEET FAILURE: HFpEF AND DIABETES 

Targeting the Diagnosis of HFpEF 
Justin Ezekowitz, MB BCh 

New and Emerging Heart Failure Therapies: 2018 and Beyond 
John McMurray, MD 

Diabetic Cardiomyopathy: Real or Imagined? 
Kim Connelly, MBBS, PhD

PLENARY Q&A

FLASH SCIENCE TRAINEE PRESENTATIONS

CHFS CLINICAL WORKSHOPS III

Nursing: Initiation & Titration of HF Medications 
Karen Harkness, RN, PhD; Serge Lepage, MD 

Advanced HF Therapies: When to Refer Patients 
Stephanie Poon, MD 

Imaging Tools for HF in 2018 
Carolina Alba, MD; Nowell Fine, MD

TED ROGERS CENTRE SCIENTIFIC SESSION: THE IMPORTANCE OF GENOMICS TO OUR UNDERSTANDING OF HEART DISEASE

Genomic-guided Therapies: Can We Cure Cardiomyopathy? 
Carolyn Ho, MD

How Deep Learning Can Predict Cardiac Arrest
Anna Goldberg, PhD 

A Novel Biomarker for Arrhythmogenic Cardiomyopathy 
Robert Hamilton, MD

LUNCH SYMPOSIUM

Interrupting the Pathway of Heart Failure 
Jonathan Howlett, MD (Chair); Karen Harkness, RN, PhD; John McMurray, MD; Sean Virani, MD

LUNCH SYMPOSIUM Q&A

JOINT PLENARY: WE MUST KNOW ABOUT CARDIOTOXICITY 

Why Cardiologist Must Care About Cancer Immunotherapy 
Javid Moslehi, MD 

Clonal Hematopoiesis: A Pathway to Cancer, A Pathway to Heart Disease 
Aaron Schimmer, MD 

Novel Diagnosis and Treatment of Cardiac Amyloidosis: Can We Cure the Incurable? 
Natalie Galant, PhD

PLENARY Q&A